James Robert Burke

Professor of Neurology

Neurology, Behavioral Neurology

Duke Box 3333, Room 201 B Bryan Research Bldg, Durham, NC 27710

932 Morreene Rd, Box 2900, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education

Academic Experience

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities

Selected Grants

Cognitive Training to Reduce Cognitive Impairment: The PACT Trial

ResearchPhysician · Awarded by University of South Florida · 2021 - 2027

Improving the lives of persons living with dementia and their families through person-centered measurement of home time

ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2026

Assessing the feasibility and acceptability of a Time Restricted Feeding intervention among older adults with Mild Cognitive Impairment

ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2026

Open-Label Extension of Studies ATH-1017-0201 and ATH-1017-0202 in Subjects with Mild to Moderate Alzheimer¿s Disease

Clinical TrialPrincipal Investigator · Awarded by Athira Pharma, Inc. · 2021 - 2026

AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects W

Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2020 - 2025

Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2020 - 2025

Combination anti-amyloid therapy for preclinical Alzheimer's disease

Clinical TrialPrincipal Investigator · Awarded by University of Southern California · 2019 - 2025

Pesticides, Olfaction, and Prodromal Neurodegeneration Among US Farmers

ResearchInvestigator · Awarded by Michigan State University · 2019 - 2025

A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease

Clinical TrialPrincipal Investigator · Awarded by Athira Pharma, Inc. · 2021 - 2024

The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease

Clinical TrialPrincipal Investigator · Awarded by University of Southern California · 2019 - 2024

A 72-Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (AD) (Stage 3 AD) to Evaluate the Effect on Cognitive and Functional Impairment, Safety, and Tolerabilit

Clinical TrialPrincipal Investigator · Awarded by Neuraly · 2021 - 2023

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2019 - 2022

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2016 - 2021

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2017 - 2021

Alzheimer's Disease, Genes, and Pesticide Use in the Agricultural Health Study

ResearchInvestigator · Awarded by National Institutes of Health · 2014 - 2021

A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2016 - 2020

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals

Clinical TrialInvestigator · Awarded by Brigham and Women's Hospital · 2015 - 2020

A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.

Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceuticals North America Inc. · 2015 - 2019

A Phase III Clinical Trial to Study the Efficacy & Safety of MK-8931 (SCH900931) in subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2019

A DB, Randomized, Placebo Controlled, Parallel Group Study to Qualify a Biomarker Algorithm for Risk of Developing MCI due to AD and to Test the S&E of Pioglitazone (AD-4833 SR 0.8 mg QD) Delay Onset of MCI due AD in Cognitively Normal Subjects.

Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceuticals North America Inc. · 2013 - 2019

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2017 - 2018

Lifestyle, CVD Risk and Cognitive Impairment

ResearchCo Investigator · Awarded by National Institutes of Health · 2011 - 2018

Caregivers' Reactions and Experience: Imaging Dementia - Evidence for Amyloid Scanning - CARE IDEAS

ResearchCo Investigator · Awarded by Brown University · 2016 - 2017

Novel Retinal Biomarkers for Early Detection of Alzheimer's Disease

ResearchCo Investigator · Awarded by Alzheimer's Association · 2013 - 2016

IPA - John F Ervin

ResearchPrincipal Investigator · Awarded by Durham Veterans Affairs Medical Center · 2013 - 2014

Metabolic Signatures for Alzheimer's Disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2011

Epidemiology of Dementia in Cache County, Utah

ResearchCo Investigator · Awarded by National Institutes of Health · 1994 - 2011

NIH State of the Science Conference on Preventing Alzheimer's Disease and Cognitive Decline

ResearchInvestigator · Awarded by Agency for Healthcare Research and Quality · 2008 - 2010

Same

ResearchInvestigator · Awarded by National Institutes of Health · 1989 - 2008

Admin Suppl - Novel therapeutics in Parkinson's disease: Identification of alpha-synuclein binding peptides by screening

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003

Manipulation of polyglutamine-protein interactions

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003

NINDS Administrative supplement for FDA-approved compound screens for neurodegeneration

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2000 - 2003

Genetic Epidemiolgy Of Alzheimer Disease In Twins

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1998

Arly Genes And Kindling Development

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1996

Early Gene And Kindling Development

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1996

Early Genes And Kindling Development - Cida

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1996

Early Genes And Kindling Development

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1996